Abstract: An apparatus and method are presented comprising one or more sensors or cameras configured to rotate about a central motor. In some examples, the motor is configured to travel at a constant linear speed while the one or more cameras face downward and collect a set of images in a predetermined region of interest. The apparatus and method are configured for image acquisition with non-sequential image overlap. The apparatus and method are configured to eliminate gaps in image detection for fault-proof collection of imagery for an underwater survey. In some examples, long baseline (LBL) is utilized for mapping detected images to a location. In some examples, ultra-short baseline (USBL) is utilized for mapping detected images to a location. The apparatus and method are configured to utilize a simultaneous localization and mapping (SLAM) approach.

Abstract: Cell-stored barcoded viral protein deep mutational scanning libraries are described. The libraries can be used to map resistance mutations to therapeutic treatments. The libraries can be used to predict viruses that become resistant to therapeutic compounds and/or may more easily evolve to infect new species. The libraries can also be used to more safely study dangerous viruses that normally require high safety biocontainment facilities. The libraries include features that allow efficient collection and assessment of informative data, obviating many bottlenecks of previous approaches.

Abstract: The present invention provides a compound having the structure: wherein R1, R2, R3, R4, and R5 are each independently H, halogen, CF3 or C1-C4 alkyl; R4 is H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterobicycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

Abstract: Provided are organoboron compounds. Also provided are formulations comprising these organoboron compounds. Further provided are OLEDs and related consumer products that utilize these organoboron compounds.

Abstract: A method of preparing a heterojunction material, includes forming a first transition metal on a substrate, forming a second transition metal on the first transition metal, and performing a plasma process containing a chalcogen source on the substrate. The first transition metal and the second transition metal are different from each other.

Abstract: Polymer composite photonic crystal materials are disclosed as coatings which have high reflection (>30%) in a specific range of the electromagnetic spectrum, such as ultraviolet (<400 nm), visible (Vis, 400 nm-700 nm), or near-infrared radiation range (NIR, 700-2000 nm), and relatively low reflection (<20% reflection) in a second, different range of the electromagnetic spectrum. Surprisingly, it was found that through a formulation and additives approach, the optical properties of polymer composite photonic crystal films can be selectively modified from a variety of different coating methods, including spray deposition.

Abstract: Methods of encoding and decoding a speech signal using a neural network model that recognizes sound sources, and encoding and decoding apparatuses for performing the methods are provided. A method of encoding a speech signal includes identifying an input signal for a plurality of sound sources; generating a latent signal by encoding the input signal; obtaining a plurality of sound source signals by separating the latent signal for each of the plurality of sound sources; determining a number of bits used for quantization of each of the plurality of sound source signals according to a type of each of the plurality of sound sources; quantizing each of the plurality of sound source signals based on the determined number of bits; and generating a bitstream by combining the plurality of quantized sound source signals.

Abstract: The present disclosure provides methods of making nicotinoyl riboside compounds or derivatives of formula (I): wherein X?, Z1, Z2, n, R1, R2, R3, R4, R5, R6, R7, and R8 are described herein, reduced analogs thereof, modified derivatives thereof, phosphorylated analogs thereof, and adenylyl dinucleotide conjugates thereof, or salts, solvates, or prodrugs thereof; and novel crystalline forms thereof.

Abstract: The present disclosure provides methods for generating MAGE-B2 specific T cells and compositions comprising engineered MAGE-B2-specific T cell receptors. Further provided are methods of treating cancer comprising administering the MAGE-B2-specific T cells.

Abstract: Glaucoma or pathogenic intraocular pressure is treated by locally administering to an eye in need thereof formulations of a Wnt5a receptor inhibitor.

Abstract: Nanoporous selective sol-gel ceramic membranes, selective-membrane structures, and related methods are described. Representative ceramic selective membranes include ion-conductive membranes (e.g., proton-conducting membranes) and gas selective membranes. Representative uses for the membranes include incorporation into fuel cells and redox flow batteries (RFB) as ion-conducting membranes.

Abstract: Universal human induced pluripotent stem cells (universal hiPSCs) and a method of forming the same are provided in the disclosure, including the following steps: providing a first cell group including human stem cells; providing a second cell group including human mononuclear cells; in some embodiments, the second cell group further includes human stem cells, in which the human stem cells of the second cell group are allogenic cells from the first cell group; mixing the first cell group and the second cell group to form cell mixture; maintaining the cell mixture at a temperature below 30° C. for at least one day; reprogramming the human stem cells of the cell mixture to obtain universal hiPSCs. The universal hiPSCs includes human leukocyte antigen-1 (HLA class I) gene and human leukocyte antigen-2 (HLA class II) gene, but no HLA class I and HLA class II expressions.

Abstract: A photovoltaic system includes a photovoltaic cell including a sun tracker, a top surface configured to generate electrical energy from the incident sunlight, and a bottom surface configured to thermally dispel heat generated by the photovoltaic cell; at least one mirror including a reflective surface; a plurality of actuators securing the at least one mirror the photovoltaic cell; at least one actuator pump connected to the plurality of actuators and configured to extend or retract the plurality of actuators and adjust the distance of the at least one mirror from the top surface; a heat exchanger thermally coupled to the bottom surface of the photovoltaic cell; and a fluid pump connected to the heat exchanger and configured to circulate the fluid through the heat exchanger.

Abstract: A stretchable substrate according to an embodiment of the present invention comprises a first modulus region which has a first modulus, a second modulus region which is located in a plane direction with respect to the first modulus region and has a second modulus higher than the first modulus, and a third modulus region which is located between the first modulus region and the second modulus region and has an interface modulus which gradually changes between the first modulus and the second modulus, wherein the interface modulus of the third modulus region may be constant in the thickness direction thereof.

Abstract: A method for forming a graphene-reinforced polymer matrix composite is disclosed. The method includes distributing graphite microparticles into a molten thermoplastic polymer phase; and applying a succession of shear strain events to the molten polymer phase so that the molten polymer phase exfoliates the graphite successively with each event until at least 50% of the graphite is exfoliated to form a distribution in the molten polymer phase of single- and multi-layer graphene nanoparticles less than 50 nanometers thick along the c-axis direction.

Abstract: The present disclosure provides methods of treating cancer in a patient determined to have a HER2 exon 19 mutation, such as a point mutation, by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.

Abstract: The present invention provides methods and compositions for treating and preventing lung injuries due to or associated with coronavirus infections that cause Severe Acute Respiratory Syndrome, including COVID-19. More specifically the present invention provides methods for treating or preventing the lung injuries associated with SARS-CoV-2 infections, such as acute lung injury (ALI), lung fibrosis, and acute respiratory distress syndrome (ARDS). The methods comprise administering a therapeutically effective amount of a pharmaceutical composition comprising a protein kinase inhibitor compound having MAP3K2/MAP3K3 inhibition activity, such as pazopanib or nintedanib, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, to a patient in need thereof. The present invention also provides devices for administering the compositions.

Abstract: Systems, methods and apparatus are included that are configured to model microvascular obstruction (MVO) in patients. According to one aspect of the present disclosure, a multi-scale model is configured to mimic myocardial microcirculation of coronary vessels. The model includes collaterals configured to provide alternative pathways possibly bypassing the MVO, and configured to model coronary artery compliance for spatially resolved fluid transport through the coronary vessels. The model is configured to simulate the MVO by increasing flow resistance in at least one of the modelled coronary vessels, or by blocking the at least one of the modelled coronary vessels completely. The model is also configured to mimic behavior of fluid transport in the coronary vessels during diagnostics or treatment, to design and optimize therapy protocols for the MVO.

Abstract: An anomaly flow detection device and an anomaly flow detection method thereof are provided.

Abstract: There is provided a biological gas measurement device that continuously collects biological gas, and is able to immediately and chronologically measure a target substance from the collected biological gas. A skin gas measurement device includes a biological gas collector 10 having an aperture portion 11 in a side thereof that faces a living body, and having a recessed portion 12 that is connected with the aperture portion 11 and serves as a space for collecting biological gas, a measurement device 100 that measures a target substance in the biological gas collected by the biological gas collector 10, an outflow path 40 through which collected biological gas is discharged from the recessed portion 12 to the measurement device 100, and a correction device 124 that corrects measurements of the target substance performed by the measurement device 100, and enables measurement results of the target substance from which effects of moisture present inside the outflow path 40 have been excluded to be output.